What does Phibro Animal Health do and what are its main business segments?

What is Phibro Animal Health's gross profit margin?

What were the key takeaways from Phibro Animal Health's earnings call?

Did Phibro Animal Health beat or miss consensus estimates last quarter?

What guidance did Phibro Animal Health's management provide for the next earnings period?

What factors drove the changes in Phibro Animal Health's revenue and profit?

What is the market's earnings forecast for Phibro Animal Health next quarter?

What is Phibro Animal Health's latest dividend and current dividend yield?

- **Revenue Surge**: Q1 2026 net sales up 40% to $363.9M, with Animal Health segment growing 55%.
- **MFA Dominance**: Medicated Feed Additives (MFA) sales jumped 81%, driving 85% EBITDA growth.
- **Companion Innovation**: Launch of Restoris dental gel and licensed therapeutic compound to address unmet companion animal needs.
- **Financial Health**: Adjusted EBITDA $102.7M (+102%), with FY26E guidance for 28% EBITDA growth.
- **Strategic Expansion**: Companion animal focus via dental care solutions, leveraging protein demand trends.


**【CEO Opening Remarks】**
- **Strong Q1 Performance**: Animal Health segment revenue grew 55% YoY, driven by 81% growth in Medicated Feed Additives (MFA) and 25% increase in vaccines.
- **Integration Success**: Seamless integration of the acquired MFA portfolio, with legacy business contributing 11% growth.
- **Consumer Trends**: Research shows GLP-1 users are shifting to high-quality proteins, supporting long-term demand for animal health products.
- **Innovation**: Launch of Restoris dental gel and a licensed therapeutic compound for companion animals, signaling expansion into companion care.

**【CFO Financial Highlights】**
- **Topline Growth**: Q1 net sales $363.9M (+40% YoY), with Animal Health segment at $283.5M (+55% YoY).
- **Profitability**: Adjusted EBITDA $102.7M (+102% YoY), driven by MFA, vaccines, and cost control.
- **Segment Breakdown**: MFA & Other (+81%), Nutritional Specialties (+13%), Vaccines (+25%).
- **Guidance**: FY26E sales $1.425B-$1.475B, EBITDA $230M-$240M, reflecting 28% growth.
- **Leverage**: Gross leverage 3.3x, net leverage 2.9x, with $85M cash on hand.

**【Q&A Highlights】**
- **Sustainability of Growth**: Legacy MFA demand driven by protein consumption trends, with no material one-time items.
- **Margin Dynamics**: Q1 margin favorability from high-margin products, but expect slight decline due to Restoris investments.
- **Companion Animal Strategy**: Dental care as unmet need; Restoris enables non-surgical treatment, freeing up vet capacity for high-value procedures.
- **Market Position**: Strong presence in key livestock markets, complemented by MFA acquisition in Asia and Europe.
- **R&D Focus**: Targeting innovation gaps in companion animals, avoiding direct competition with big 4 players.


PAHC

PAHC fundamentals

You can ask Aime